Dr. Ghobadi on the Safety of CAR T-Cell Therapy in Hematologic Malignancies

Video

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the safety of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies.

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the safety of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies.

CAR T-cell therapy is a relatively safe treatment, explains Ghobadi. The rate of complications and mortality associated with this approach are similar to what is seen with autologous stem cell transplant, with these rates ranging from 2% to 3% with transplant and 3% to 5% with the CAR-T. The rate of high-grade cytokine release syndrome that requires going to the intensive care unit, or experiencing neurotoxicity or other brain complications such as seizures and confusion, is relatively high but almost always reversible, adds Ghobadi.

As more research is done, Ghobadi explains that not only will physicians look for a way to mitigate the side effects of the therapy but investigate combinations with the highest curative potential.

Recent Videos
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Related Content
© 2025 MJH Life Sciences

All rights reserved.